Naftifine
As of the edition of 20 October 2026, Naftifine is a small molecule: marketed, first approved in 1988 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Naftin
- First approved
- 29 February 1988 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Legacy Pharma Inc Sezc
- Registered trials
- 12, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 3 | 6 | 6 | 0 | 0 |
| Phase 4 | 3 | 3 | 0 | 0 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Earlier holder | 1988 to now |
| Merz Pharma GmbH & Co. KGaA | Later holder | 2013 to now |
| Legacy Pharma Inc Sezc | Acquired holder | 2026 to now |